L.a rFIX derivative
:Haemostatic agent
:Phase 1
Novo Nordisk is developing a glyco-PEGylated derivative of rFIX for prophylactic use as well as treatment of bleeding episodes of patients with Haemophilia B.
- Company announcements
- No company announcements matching the search criteria
- Press releases
- No press releases matching the search criteria
- Scientific abstracts
- Accreditation and Quality Assurance (2002)
- Accreditation and Quality Assurance (2003)
- Accreditation and Quality Assurance (2005)
- Read more scientific abstracts
